Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-na<spacing diaeresis>ive patients with myelofibrosis

被引：0
作者：
Rampal, Raajit
Grosicki, Sebastian
Chraniuk, Dominik
Abruzzese, Elisabetta
Bose, Prithviraj
Gerds, Aaron Thomas
Vannucchi, Alessandro M.
Palandri, Francesca
Lee, Sung-Eun
Gupta, Vikas
Lucchesi, Alessandro
Kuykendall, Andrew Tucker
Mesa, Ruben A.
Kiladjian, Jean-Jacques
Talpaz, Moshe
Harris, Morgan
Wu, Manlei
Brown, Barbara
Harrison, Claire
Mascarenhas, John
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY USA
[2] Med Univ Silesia, Katowice, Poland
[3] Wojewodzki Szpital Zespolony L Rydygiera, Hematol Ward, Torun, Poland
[4] Tor Vergata Univ, Dept Hematol, S Eugenio Hosp, Rome, Italy
[5] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[6] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA
[7] Univ Florence, Dept Clin & Expt Med, Florence, Italy
[8] IRCCS Azienda Osped Univ Bologna, Ist Ematol S Orsola Malpighi, Bologna, Italy
[9] Catholic Univ Korea, Dept Hematol, Seoul St Marys Hosp, Coll Med, Seoul, South Korea
[10] Princess Margaret Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada
[11] IRCCS Ist Romagnolo & Cura Tumori IRST Dino Amado, Meldola, Italy
[12] Mofitt Canc Ctr, Tampa, FL USA
[13] Wake Forest Univ, Atrium Hlth Wake Forest Baptist Comprehens Canc C, Sch Med, Winston Salem, NC USA
[14] Univ Paris, Clin Invest Ctr, Hop St Louis, Paris, France
[15] Univ Michigan, Comprehens Canc Ctr, London, England
[16] Constellat Pharmaceut, Boston, MA USA
[17] MorphoSys US Inc, Boston, MA USA
[18] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England
[19] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6502
引用
收藏
页数：1
相关论文
共 50 条
[11]   Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naive Myelofibrosis Patients [J].
Harrison, Claire N. ;
Patriarca, Andrea ;
Mascarenhas, John ;
Kremyanskaya, Marina ;
Hoffman, Ronald ;
Schiller, Gary J. ;
Leber, Brian ;
Devos, Timothy ;
Kabir, Sujan ;
Senderowicz, Adrian ;
Mertz, Jennifer ;
Trojer, Patrick ;
Shao, James ;
Gupta, Vikas .
BLOOD, 2019, 134
[12]   A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis [J].
Daver, Naval G. ;
Kremyanskaya, Marina ;
O'Connell, Casey ;
Dao, Kim-Hien ;
Oh, Stephen T. ;
Gerds, Aaron T. ;
Verstovsek, Srdan ;
Erickson-Viitanen, Sue ;
Zhou, Feng ;
Assad, Albert ;
Yacoub, Abdulraheem .
BLOOD, 2018, 132
[13]   Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF) [J].
Yacoub, Abdulraheem ;
Borate, Uma ;
Rampal, Raajit ;
Ali, Haris ;
Wang, Eunice S. ;
Gerds, Aaron T. ;
Hobbs, Gabriela ;
Kremyanskaya, Marina ;
Winton, Elliott ;
O'Connell, Casey ;
Goel, Swati ;
Oh, Stephen ;
Schiller, Gary J. ;
Assad, Albert ;
Erickson-Viitanen, Sue ;
Zhou, Feng ;
Daver, Naval .
BLOOD, 2021, 138
[14]   CPI-0610, a bromodomain and extraterminal domain protein (bet) inhibitor, in combination with ruxolitinib, in jak-inhibitor-naive myelofibrosis patients: update of manifest phase 2 study [J].
Mead, Adam ;
Mascarenhas, John ;
Talpaz, Moshe ;
Patriarca, Andrea ;
Devos, Timothy ;
Palandri, Francesca ;
Passamonti, Francesco ;
Rampal, Raajit ;
Kremyanskaya, Marina ;
Scandura, Joseph ;
Somervaille, Tim ;
Wondergem, Marielle ;
Granacher, Nikki ;
Hoffman, Ronald ;
Gupta, Vikas ;
Luptakova, Katarina ;
Wang, Jing ;
Christo, Jessica ;
Colak, Gozde ;
Shao, James ;
Bobba, Suresh ;
Trojer, Patrick ;
Verstovsek, Srdan ;
Harrison, Claire .
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 :96-96
[15]   CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) PROTEIN INHIBITOR, IN COMBINATION WITH RUXOLITINIB, IN JAK INHIBITOR-NAIVE MYELOFIBROSIS PATIENTS: UPDATE OF MANIFEST PHASE 2 STUDY [J].
Palandri, F. ;
Mascarenhas, J. ;
Harrison, C. ;
Patriarca, A. ;
Devos, T. ;
Rampal, R. ;
Vannucchi, A. ;
Passamonti, F. ;
Mead, A. ;
Kremyanskaya, M. ;
Somervaille, T. ;
Wondergem, M. ;
Hoffman, R. ;
Luptakova, K. ;
Wang, J. ;
Colak, G. ;
Shao, J. ;
Bobba, S. ;
Trojer, P. ;
Verstovsek, S. ;
Gupta, V. .
HAEMATOLOGICA, 2021, 106 (10) :5-6
[16]   CPI-0610, a bromodomain and extraterminal domain (BET) protein inhibitor, in combination with ruxolitinib, in JAK-inhibitor-naive myelofibrosis patients: Update of MANIFEST phase 2 study [J].
Platzbecker, U. ;
Mascarenhas, J. ;
Harrison, C. ;
Patriarca, A. ;
Devos, T. ;
Palandri, F. ;
Rampal, R. ;
Vannucchi, A. ;
Mead, A. ;
Kremyanskaya, M. ;
Somervaille, T. ;
Wondergem, M. ;
Hoffman, R. ;
Luptakova, K. ;
Wang, J. ;
Colak, G. ;
Shao, J. ;
Bobba, S. ;
Trojer, P. ;
Verstovsek, S. ;
Gupta, V .
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 :158-158
[17]   A Phase 2 Study of the Safety and Efficacy of INCB050465 in Combination with Ruxolitinib in Patients with Myelofibrosis (MF) [J].
Daver, Naval ;
Dao, Kim-Hien ;
Assad, Albert ;
Verstovsek, Srdan .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 :S351-S351
[18]   Phase 2 Study to Assess the Safety and Efficacy of Bomedemstat (MK3543) in Combination with Ruxolitinib in Patients with Myelofibrosis [J].
Gill, Harinder ;
Au, Lester ;
Leung, Garret Man Kit ;
Tsai, Dorothy ;
Yim, Rita ;
Chin, Lynn ;
Li, Vivian ;
Lee, Paul ;
Leung, Rock Yuk Yan ;
Lee, Elaine ;
Rienhoff, Hugh Young, Jr. ;
Kwong, Yok Lam .
BLOOD, 2023, 142
[19]   Manifest-2, a global, phase 3, randomized, double-blind, active-control study of CPI 0610 and ruxolitinib vs. placebo and ruxolitinib in JAKI-treatment-naive myelofibrosis patients [J].
Mead, Adam ;
Mascarenhas, John ;
Gerds, Aaron ;
Luptakova, Katarina ;
Christo, Jessica ;
Wang, Jing ;
Colak, Gozde ;
Shao, James ;
Bobba, Suresh ;
Trojer, Patrick ;
Humphrey, Jeffrey ;
Verstovsek, Srdan ;
Harrison, Claire .
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 :101-102
[20]   Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial [J].
Shimoda, Kazuya ;
Komatsu, Norio ;
Matsumura, Itaru ;
Ikeda, Kazuhiko ;
Hino, Masayuki ;
Hidaka, Michihiro ;
Maeda, Yoshinobu ;
Kondo, Takeshi ;
Fujisaki, Tomoaki ;
Shoshi, Keita ;
Azuma, Kyoichi ;
Fukushima, Ryuichi ;
Kawashima, Jun ;
Kosugi, Hiroshi .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (03) :314-324
12345